The global influenza virus B infection drug market is anticipated to grow at a significant CAGR during the forecast period. Influenza viruses cause nose, throat, and sometimes lungs infection. Its symptoms include fever, a cough, sore throat, and body aches. Additionally, type B influenza can cause more severe symptoms than a common cold however, in some cases, there is no need for medical attention. The major factor accelerating the growth of the market is the increasing prevalence of influenza infection across the globe.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/influenza-virus-b-infection-drug-market
Furthermore, the market is also growing due to new FDA approvals. For instance, in November 2020, Roche announced the approval of a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) from the US Food and Drug Administration (FDA). It is the first single-dose influenza medicine approved for post-exposure prophylaxis used as a treatment to prevent influenza in people age 12 years and older due to coming in contact with someone with influenza.
Some major players in the market include AstraZeneca Plc, F. Hoffmann-La Roche AG, and GlaxoSmithKline Plc, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in July 2019, Gilead Sciences, Inc. announced that it has received an antiviral deal with Novartis. The deal was aimed to gain exclusive global rights to preclinical programmes which involve candidates for the treatment of various viral infections such as herpes viruses, human rhinovirus and influenza.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Distribution Channel
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- AstraZeneca Plc, F. Hoffmann-La Roche AG, and GlaxoSmithKline Plc, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Influenza Virus B Infection Drug Market Report by Segment
By Type
- Peramivir
- Zanamivir
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
A full report of Influenza Virus B Infection Drug Market is available at: https://www.omrglobal.com/industry-reports/influenza-virus-b-infection-drug-market
Influenza Virus B Infection Drug Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca Plc
- Hoffmann-La Roche AG
- GlaxoSmithKline Plc
